|
Post by harshal1981 on Feb 26, 2014 11:45:16 GMT -5
I am planning to drive down to DC for attending the AdCom in person. This is my first AdCom attendance. Was wondering if any one can tell me what is the process to get in to the meeting hall? Do they sell any passes? Do you have to register in advance? Do they plan to accomodate enough people or they are in small halls and run out of capacity more often and majority of audience is stuck out side? How early people start to line up / show up at the venue?
I certainly don't want to miss this meeting so any help would be highly appreciated.
|
|
|
Post by Chris on Feb 26, 2014 12:25:54 GMT -5
CDER April 1, 2014 8:00 a.m. to 5:00 p.m. The Marriott Inn and Conference Center University of Maryland University College (UMUC), Potomac Ballroom 3501 University Blvd. East Hyattsville, Maryland Agenda The committee will discuss new drug application (NDA) 22-472, proposed trade name AFREZZA (TECHNOSPHERE Insulin Inhalation System), 3 unit and 6 unit cartridges for oral inhalation, manufactured by MannKind Corporation. The proposed indication (use) for this application is to improve glycemic control in adult patients with type 1 or type 2 diabetes mellitus. Meeting Materials FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting Background Material 2014 Meeting Materials, Endocrinologic and Metabolic Drugs Advisory Committee Public Participation Information Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before March 18, 2014. Oral presentations from the public will be scheduled between approximately 1:00 p.m. to 2:00 p.m. on April 1, 2014. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before March 10, 2014. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by March 11, 2014. Webcast Information CDER plans to provide a free of charge, live webcast of the April 1, 2014, meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. While CDER is working to make webcasts available to the public for all advisory committee meetings held at the White Oak campus, there are instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible. Further information regarding the webcast, including the web address for the webcast, will be made available at least 2 days in advance of the meeting at the following website: 2014 Meeting Materials, Endocrinologic and Metabolic Drugs Advisory Committee CDER plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available. Contact Information Karen Abraham-Burrell, PharmD Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Avenue WO31-2417 Silver Spring, MD 20993 Phone: 301-796-9001 Fax: 301-847-8533 E-mail: EMDAC@fda.hhs.gov FDA Advisory Committee Information Line 1-800-741-8138 (301-443-0572 in the Washington DC area)- follow the prompts to the desired center or product area Please call the Information Line for up-to-date information on this meeting. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Web site and call the FDA Advisory Committee Information Line to learn about possible modifications before coming to the meeting
------. Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Karen Abraham-Burrell at (301) 796-9001 at least 7 days in advance of the meeting. Information regarding ground transportation, airport information, lodging, driving directions and visitor parking, and security can be accessed at: Public Meetings at the FDA White Oak Campus. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).
|
|
|
Post by krj00 on Feb 26, 2014 12:51:19 GMT -5
|
|
|
Post by otherottawaguy on Feb 26, 2014 19:47:06 GMT -5
Snag a wheelchair or show up with a white cane and your in the front row... although not sure the white can in the front row is a benefit to that category in this instance.
OOG
|
|
|
Post by harshal1981 on Feb 26, 2014 23:26:12 GMT -5
any one ?
|
|
|
Post by Chris on Feb 27, 2014 0:15:03 GMT -5
|
|